P21675 (TAF1_HUMAN) Homo sapiens (Human)
Transcription initiation factor TFIID subunit 1 UniProtKBInterProSTRINGInteractive Modelling
1893 aa; Sequence (Fasta) ; (Isoform 1; Isoform 13; Isoform 14; Isoform 15; Isoform 16; Isoform 17; Isoform 18; Isoform 19; Isoform 20; Isoform 21; Isoform 22; Isoform 23; Isoform 24; Isoform 25)
It is possible new templates exist for this target since these models were created.
Available Structures
60 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Human TFIID canonical state |
Heteromer O00268; P20226; P49848; Q12962; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q7Z7C8; | 100.0 | ||||
| TFIID lobe C subcomplex |
Heteromer P49848; Q15545; Q6P1X5; Q7Z7C8; | 100.0 | ||||
| SCP promoter-bound TFIID-TFIIA in initial TBP-loading state |
Heteromer O00268; P20226; P49848; P52655; P52657; Q12962; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q7Z7C8; | 100.0 | ||||
| SCP promoter-bound TFIID-TFIIA in post TBP-loading state |
Heteromer O00268; P20226; P49848; P52655; P52657; Q12962; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q7Z7C8; | 100.0 | ||||
| Structure of transcribing complex 9 (TC9), the initially transcribing complex with Pol II positione… |
Heteromer A0A481BYI6; A0A493TD97; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; A0A8D1DPV6; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P29083; P29084; P32780; P35269; P49848; P51948; P52655; P52657; P60899; P85421; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759; | 100.0 | 17×ZN; 1×SF4; 1×MG; 1×W0F; | |||
| Structure of transcribing complex 5 (TC5), the initially transcribing complex with Pol II positione… |
Heteromer A0A481BYI6; A0A493TD97; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; A0A8D1DPV6; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P29083; P29084; P32780; P35269; P49848; P51948; P52655; P52657; P60899; P85421; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759; | 100.0 | 17×ZN; 1×SF4; 1×MG; 1×W0F; | |||
| Structure of transcribing complex 8 (TC8), the initially transcribing complex with Pol II positione… |
Heteromer A0A481BYI6; A0A493TD97; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; A0A8D1DPV6; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P29083; P29084; P32780; P35269; P49848; P51948; P52655; P52657; P60899; P85421; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759; | 100.0 | 17×ZN; 1×SF4; 1×MG; 1×W0F; | |||
| Structure of transcribing complex 6 (TC6), the initially transcribing complex with Pol II positione… |
Heteromer A0A481BYI6; A0A493TD97; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; A0A8D1DPV6; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P29083; P29084; P32780; P35269; P49848; P51948; P52655; P52657; P60899; P85421; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759; | 100.0 | 17×ZN; 1×SF4; 1×MG; 1×W0F; | |||
| Structure of transcribing complex 3 (TC3), the initially transcribing complex with Pol II positione… |
Heteromer A0A481BYI6; A0A493TD97; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; A0A8D1DPV6; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P29083; P29084; P32780; P35269; P49848; P51948; P52655; P52657; P60899; P85421; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759; | 100.0 | 17×ZN; 1×SF4; 1×W0F; 1×MG; | |||
| Structure of transcribing complex 4 (TC4), the initially transcribing complex with Pol II positione… |
Heteromer A0A481BYI6; A0A493TD97; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; A0A8D1DPV6; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P29083; P29084; P32780; P35269; P49848; P51948; P52655; P52657; P60899; P85421; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759; | 100.0 | 17×ZN; 1×SF4; 1×MG; 1×W0F; | |||
| Structure of transcribing complex 2 (TC2), the initially transcribing complex with Pol II positione… |
Heteromer A0A481BYI6; A0A493TD97; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; A0A8D1DPV6; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P29083; P29084; P32780; P35269; P49848; P51948; P52655; P52657; P60899; P85421; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759; | 100.0 | 17×ZN; 1×SF4; 1×W0F; 1×MG; | |||
| Structure of transcribing complex 7 (TC7), the initially transcribing complex with Pol II positione… |
Heteromer A0A481BYI6; A0A493TD97; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; A0A8D1DPV6; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P29083; P29084; P32780; P35269; P49848; P51948; P52655; P52657; P60899; P85421; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759; | 100.0 | 17×ZN; 1×SF4; 1×MG; 1×W0F; | |||
| TFIID-based holo PIC on SCP promoter |
Heteromer A0A481BYI6; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P24928; P29083; P29084; P32780; P35269; P49848; P50613; P51946; P51948; P52655; P52657; P60899; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759; | 100.0 | 17×ZN; 1×SF4; 1×MG; | |||
| TFIID-based intermediate PIC on PUMA promoter |
Heteromer A0A287ADR4; A0A4X1TRS6; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VYD0; A0A7M4DUC2; F1RKE4; I3LCB2; I3LCH3; I3LGP4; I3LSI7; O00268; P13984; P20226; P29083; P29084; P35269; P49848; P52655; P52657; P60899; Q00403; Q12962; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q7Z7C8; | 100.0 | 10×ZN; 1×MG; | |||
| TFIID in rearranged conformation |
Heteromer O00268; P20226; P49848; P52655; P52657; Q12962; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q7Z7C8; | 100.0 | ||||
| TFIID-based core PIC on PUMA promoter |
Heteromer A0A287ADR4; A0A4X1TRS6; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VYD0; A0A7M4DUC2; F1RKE4; I3LCB2; I3LCH3; I3LGP4; I3LSI7; O00268; P13984; P20226; P35269; P49848; P52655; P52657; P60899; Q00403; Q12962; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q7Z7C8; | 100.0 | 9×ZN; 1×MG; | |||
| p53-bound TFIID-based core PIC on HDM2 promoter |
Heteromer A0A287ADR4; A0A4X1TRS6; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VYD0; A0A7M4DUC2; F1RKE4; I3LCB2; I3LCH3; I3LGP4; I3LSI7; O00268; P13984; P20226; P35269; P49848; P52655; P52657; P60899; Q00403; Q12962; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q7Z7C8; | 100.0 | 9×ZN; 1×MG; | |||
| TFIID-based intermediate PIC on SCP promoter |
Heteromer A0A287ADR4; A0A4X1TRS6; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VYD0; A0A7M4DUC2; F1RKE4; I3LCB2; I3LCH3; I3LGP4; I3LSI7; O00268; P13984; P20226; P29083; P29084; P35269; P49848; P52655; P52657; P60899; Q00403; Q12962; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q7Z7C8; | 100.0 | 10×ZN; 1×MG; | |||
| TFIID in canonical conformation |
Heteromer O00268; P20226; P49848; Q12962; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q7Z7C8; | 100.0 | ||||
| TFIID-based core PIC on SCP promoter |
Heteromer A0A287ADR4; A0A4X1TRS6; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VYD0; A0A7M4DUC2; F1RKE4; I3LCB2; I3LCH3; I3LGP4; I3LSI7; O00268; P13984; P20226; P35269; P49848; P52655; P52657; P60899; Q00403; Q12962; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q7Z7C8; | 100.0 | 9×ZN; 1×MG; | |||
| p53-bound TFIID-based holo PIC on HDM2 promoter |
Heteromer A0A481BYI6; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P24928; P29083; P29084; P32780; P35269; P49848; P50613; P51946; P51948; P52655; P52657; P60899; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759; | 100.0 | 16×ZN; 1×SF4; 1×MG; | |||
| Crystal Structure of a TAF1-TAF7 Complex in Human Transcription Factor IID |
Heteromer Q15545; | 100.0 | 2×GOL; | |||
| Structure of human TFIID-IIA bound to core promoter DNA |
Heteromer P20226; P49848; P52655; P52657; Q15545; Q6P1X5; Q7Z7C8; | 100.0 | ||||
| Human TFIID bound to promoter DNA and TFIIA |
Heteromer O00268; P20226; P49848; P52655; P52657; Q12962; Q15542; Q15545; Q16514; Q16594; Q6P1X5; Q7Z7C8; | 100.0 | ||||
| Structure of the histone chaperone CIA/ASF1-double bromodomain complex linking histone modification… |
Heteromer Q9Y294; | 100.0 | 1×SO4; | |||
| Crystal structure of TAF1 BD2 Bromodomain bound to a butyryllysine peptide |
Heteromer P62805; | 100 | 1×CA; | |||
| Crystal structure of TAF1 BD2 Bromodomain bound to a crotonyllysine peptide |
Heteromer P62805; | 100 | ||||
| Human TFIID Lobe A canonical |
Heteromer O00268; P20226; P49848; Q12962; Q15542; Q15543; Q15544; Q16514; Q16594; Q5VWG9; | 100.0 | ||||
| Crystal structure of the second bromodomain (BD2) of human TAF1 bound to PLK1 kinase inhibitor BI25… | homo-2-mer | 100 | 4×R78; | |||
| Crystal structure of the unliganded second bromodomain (BD2) of human TAF1 | homo-2-mer | 100 | 2×SO4; 14×EDO; | |||
| Crystal structure of the second bromodomain (BD2) of human TAF1 bound to dioxane | homo-2-mer | 100 | 2×SO4; 2×DIO; 22×EDO; | |||
| CRYSTAL STRUCTURE OF THE DOUBLE BROMODOMAIN MODULE FROM HUMAN TAFII250 | monomer | 100 | 1×SO4; | |||
| Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to GNE-371 | monomer | 100 | 1×G9V; 2×EDO; | |||
| Crystal Structure of the tandem bromodomains of human Transcription initiation factor TFIID subunit… | monomer | 100 | 1×TRS; | |||
| Crystal structure of the unliganded tandem bromodomain (BD1, BD2) of human TAF1 | monomer | 100 | 7×EDO; | |||
| Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 in complex with MES (2-(N-morp… | monomer | 100 | 1×MES; 3×EDO; 2×ACT; 2×FMT; | |||
| Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to mTORC1/2 inhibitor AZ… | monomer | 100 | 1×VQS; | |||
| Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-585 | monomer | 100 | 18×EDO; 1×PEG; 1×XWV; | |||
| Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 bound to ZS1-322 | monomer | 100 | 1×EIO; 3×EDO; | |||
| Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1 bound to ATR kinase inhibit… | monomer | 100 | 1×VJM; 4×EDO; | |||
| Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-295 | monomer | 100 | 1×XXV; 1×EDO; | |||
| Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ATR inhibitor AZ20 | monomer | 100 | 4×EDO; 1×VCD; 1×DMS; 1×GOL; | |||
| Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-589 | monomer | 100 | 8×EDO; 1×HEZ; 1×XWY; | |||
| Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound to ZS1-588 | monomer | 100 | 1×DMS; 3×EDO; 1×E9F; | |||
| Crystal structure of the tandem bromodomain of human TAF1 (TAF1-T) bound to ZS1-681 | monomer | 100 | 7×EDO; 1×06M; 1×DMS; | |||
| Bivalent Inhibitor UNC4512 Bound to the TAF1 Bromodomain Tandem | monomer | 100 | 2×DKH; | |||
| TAF1(2) bound to a pyrrolopyridone compound | monomer | 100 | 1×67B; 1×CA; | |||
| Second bromodomain of TAF1 bound to a pyrrolopyridone compound | monomer | 100 | 1×67C; | |||
| Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ATR kinase inhibitor AZ20 | monomer | 100 | 1×VCD; 1×EDO; 1×GOL; | |||
| Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ATR kinase inhibitor AZD67… | monomer | 100 | 1×VJM; 1×EDO; 1×SO4; | |||
| Crystal structure of the second bromodomain of human TAF1 in complex with BAY-299 chemical probe | monomer | 100 | 3×EDO; 1×7M8; | |||
| Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ZS1-580 | monomer | 100 | 1×XXS; 1×EDO; | |||
| Crystal structure of the second bromodomain (BD2) of human TAF1 bound to ZS1-322 | monomer | 100 | 1×VK1; 2×EDO; | |||
| BROMODOMAIN OF HUMAN TAF1 (2) WITH naphthyridinone compound | monomer | 100 | 2×5LV; | |||
| TAF1-BD2 bromodomain in complex with (E)-3-(6-(but-2-en-1-yl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]py… | monomer | 100 | 1×69G; | |||
| Crystal structure of the second bromodomain (BD2) of human TAF1 bound to bromosporine | monomer | 100 | 1×BMF; 1×EDO; | |||
| Crystal Structure Analysis of TAF1 Bromodomain | monomer | 100 | 1×NQY; | |||
| Crystal Structure Analysis of TAF1 Bromodomain | monomer | 100 | 1×NQV; | |||
| Crystal Structure Analysis of TAF1 Bromodomain | monomer | 100 | 1×NQP; | |||
| Crystal Structure of the second bromodomain of human Transcription initiation factor TFIID subunit … | monomer | 100 | 1×EDO; 1×GOL; | |||
6 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6dne.1.A | monomer | 0.68 | 25.11 | |||
| 8og2.1.A | monomer | 0.63 | 29.59 | |||
| 7egh.1.A | monomer | 0.60 | 100.00 | |||
| 6mzd.1.A | monomer | 0.60 | 100.00 | |||
| 8wak.1.I | monomer | 0.56 | 100.00 | |||
| 7egi.1.A | monomer | 0.55 | 100.00 | |||